Andrea Eleazar, MHS

Why oncology telehealth stalls: patients cite platform anxiety, few video offers, and in-person trust—pointing to hybrid care.

Off-the-shelf CD19 CAR T boosts MRD clearance in first-line LBCL consolidation, with no CRS/ICANS and strong outpatient community feasibility.

New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying targeted treatment decisions.

FDA fully approves brexu-cel CAR‑T for relapsed mantle cell lymphoma, with ZUMA‑2 showing deep responses and key infection-care tips for clinicians.

New CMML molecular framework links genomic classes and iCPSS scoring to predict outcomes and guide optimal stem cell transplant timing.

Statin use alongside CD19 CAR T shows longer survival and less neurotoxicity in relapsed large B-cell lymphoma, prompting calls for trials.

Same-day multidisciplinary clinics could shorten time to treatment, boost guideline adherence, and improve satisfaction in solid tumor care, a review finds.

FDA confirms brexu-cel CAR-T for relapsed mantle cell lymphoma, citing 91% response in BTK-naive patients and updated safety guidance.

New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by tumor burden and ECOG status.

Young US cancer survivors face outsized food, housing and transport insecurity; Medicaid expansion and targeted SDOH screening may improve survivorship.

Second-line axi-cel CAR T boosts quality of life in relapsed large B-cell lymphoma, with early dip then lasting recovery for older patients.

Venetoclax plus ibrutinib shows deep, durable responses in marginal zone lymphoma, with promising 5-year PFS and manageable safety in phase 2 AIM study.

Ten-year trial shows CD22 CAR T drives deep remissions in relapsed pediatric B-ALL, with transplant boosting durability and manageable toxicity.

Post-transplant gilteritinib maintenance may boost survival and reduce relapse in relapsed FLT3-mutated AML, though larger trials are still needed.

Real-world brexu-cel CAR-T data in adult R/R B-ALL show trial-like ICANS, CRS, and highlight monitoring and risk factors.

Phase 1 expansion shows Varseta-M delivers notable response rates and manageable safety in heavily pretreated metastatic colorectal cancer, with FDA registrational planning underway.

FDA signals accelerated path for givastomig in CLDN18.2+ gastric/GEJ cancer, as phase 1b data show strong responses and tolerability.

Report finds hospitals price the same cancer drugs up to 2000x apart, worsening financial toxicity and intensifying demands for real transparency.

Interim phase 1b results show off-the-shelf CD19 CAR T azer-cel drives high response rates in hard-to-treat CLL/SLL and MZL.

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Academic centers are associated with greater biliary tract cancer surgery success while minority patients and nonacademic care face gaps, urging better resource allocation.

ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.

The FDA approves a new formulation of piflufolastat F 18, enhancing prostate cancer imaging with improved efficiency and patient access.

Johns Hopkins Medicine develops a free immune atlas of pancreatic cancer trials, spotlighting blood-based signals to build stronger pancreatic cancer immunotherapy combinations.

Phase 2a data show oral namodenoson is well tolerated in heavily pretreated pancreatic cancer, with survival follow-up ongoing and FDA orphan status boosting promise.

Modeling shows zanubrutinib may cut progression and costs versus acalabrutinib in relapsed/refractory CLL, especially in high-risk patients.

FDA grants tentative approval to PNT2003, a Lutathera radioequivalent PRRT for SSTR+ GEP-NETs, paving way for wider access by 2026.

FDA confirms first-line BRAF V600E mCRC gains: encorafenib plus cetuximab with FOLFOX or FOLFIRI improves PFS and OS.

Cross-trial analysis shows zanubrutinib delivers longer progression-free survival than ibrutinib or acalabrutinib in relapsed CLL, including high-risk del(17p)/del(11q).

FDA fast-tracks PLT012, a CD36 metabolic checkpoint antibody for liver cancer, as phase 1 trial tests safety and early efficacy.